Analysis of Gastrointestinal and Hepatic Chronic Grant-versus-Host Disease Manifestations on Major Outcomes: A Chronic Grant-versus-Host Disease Consortium Study  by Pidala, Joseph et al.
Biol Blood Marrow Transplant 19 (2013) 784e791American Society for Blood
ASBMT
and Marrow TransplantationAnalysis of Gastrointestinal and Hepatic Chronic
Grant-versus-Host Disease Manifestations on Major
Outcomes: A Chronic Grant-versus-Host Disease
Consortium Study
Joseph Pidala 1,*, Xiaoyu Chai 2, Brenda F. Kurland 2, Yoshihiro Inamoto 2,
Mary E.D. Flowers 2, Jeanne Palmer 3, Nandita Khera 4, Madan Jagasia 5,
Corey Cutler 6, Mukta Arora 7, Georgia Vogelsang 8, Stephanie J. Lee 2
1H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, Florida
2 Fred Hutchinson Cancer Research Center, Seattle, Washington
3Medical College of Wisconsin, Milwaukee, Wisconsin
4Mayo Clinic Arizona, Phoenix, Arizona
5Vanderbilt University Medical Center, Nashville, Tennessee
6Dana-Farber Cancer Institute, Boston, Massachusetts
7University of Minnesota Medical Center, Minneapolis, Minnesota
8 Johns Hopkins University, Baltimore, MarylandArticle history:
Received 4 November 2012
Accepted 1 February 2013
Key Words:
Chronic GVHD
Gastrointestinal
HepaticFinancial disclosure: See Acknowl
* Correspondence and reprint req
Center, Blood and Marrow Trans
Fl 33612.
E-mail address: joseph.pidala@
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Although data support adverse prognosis of overlap subtype of chronic grant-versus-host disease (GVHD), the
importance of site of gastrointestinal (GI) and type of hepatic involvement is not known. Using data from the
Chronic GVHD Consortium observational cohort study (N ¼ 567, total of 2115 visits), we examined whether
the site of GI (esophageal, upper GI, or lower GI) and type of hepatic (bilirubin, alkaline phosphatase, alanine
aminotransferase) involvement are associated with overall survival (OS) and nonrelapse mortality (NRM),
symptoms, quality of life (QOL) and functional status measures. In multivariate analysis utilizing data from
enrollment visits only, lower GI involvement (HR, 1.67; P ¼ .05) and elevated bilirubin (HR, 2.46; P ¼ .001) were
associated with OS; both were also associated with NRM. In multivariable analysis using all visits (time-
dependent covariates), GI score greater than zero (HR, 1.69; P ¼ .02) and elevated bilirubin (HR, 3.73; P < .001)
were associated with OS; results were similar for NRM. Any esophageal involvement and GI score greater than
zero were associated with both symptoms and QOL, whereas elevated bilirubin was associated with QOL. We
found no consistent evidence that upper GI involvement, alkaline phosphatase, alanine aminotransferase, or
NIH liver score add prognostic value for survival, overall symptom burden, or QOL. These data support
important differences in patient-reported outcomes according to GI and hepatic involvement among chronic
GVHD-affected patients and identify those with elevated bilirubin or higher GI score at any time, or lower GI
involvement at cohort enrollment, as patients at greater risk for mortality under current treatment approaches.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION site of gastrointestinal (esophagus, upper, and lower GI) or
Chronic graft-versus-host disease (GVHD) is a signiﬁcant
source of morbidity, mortality, impaired patient-reported
quality of life (QOL), greater symptom burden, and pro-
longed duration of immune suppressive therapy following
allogeneic hematopoietic cell transplantation (HCT) [1-10].
Many [11,12], but not all retrospective studies [13,14] and
prospective data from the Chronic GVHD Consortium [15],
have demonstrated that overlap subtype of chronic GVHD,
deﬁned as chronic GVHD together with concurrent acute
GVHD manifestations [16], is associated with worse prog-
nosis and inferior patient-reported outcomes.
The proposed NIH Consensus criteria for organ-speciﬁc
severity grading do not distinguish between the site of
gastrointestinal (GI) or hepatic involvement but rather assign
severity according to degree of weight loss or by magnitude
of elevation of hepatic laboratory tests over the upper limit of
normal, respectively. The impact on major outcomes of eachedgments on page 791.
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13.02.001type of hepatic (transaminases, bilirubin, and alkaline phos-
phatase) manifestation of chronic GVHD is unknown.
We analyzed prospectively acquired observational cohort
data to examine whether the site of GI involvement and type
of hepatic laboratory test abnormality among patients with
chronic GVHD are associated with major clinical outcomes,
such as mortality, symptom burden, QOL, and functional
ability.
METHODS
Chronic GVHD Observational Cohort
The Chronic GVHD Consortium is a multicenter observational cohort
study of chronic GVHD-affected HCT recipients. The rationale and design of
this cohort study have been previously described [17]. In brief, included are
allogeneic HCT recipients age 2 or older with chronic GVHD requiring
systemic immunosuppressive therapy, both thosewith classic chronic GVHD
and those with overlap subtype [16]. Cases are classiﬁed as incident
(enrollment less than 3 months after chronic GVHD diagnosis) or prevalent
(enrollment 3 or more months but less than 3 years after chronic GVHD
diagnosis). Exclusion criteria include primary disease relapse and inability to
comply with study procedures.
Clinicians and patients report standardized information on chronic
GVHD organ involvement and symptoms at cohort enrollment and at serial
follow-up visits. Chronic GVHD global severity according to the NIH Chronic
GVHD Consensus is scored according to objective criteria for each organ
involved, which is summarized for an overall score of mild, moderate, orTransplantation.
Table 1
Summary of Patient and Transplantation Characteristics
Characteristics Category Count (%) Median Min Max
Site Fred Hutchinson Cancer Research Center 247 (44%)
University of Minnesota 59 (10%)
Dana-Farber Cancer institute 65 (11%)
Stanford University Medical Center 72 (13%)
Northwest Children’s Hospital 13 (2%)
Vanderbilt University Medical Center 47 (8%)
Medical College of Wisconsin 23 (4%)
Washington University Medical Center 4 (1%)
Mofﬁtt Cancer Center 35 (6%)
Memorial Sloan-Kettering Cancer Center 2 (1%)
Case type Incident 336 (59%)
Prevalent 231 (41%)
Adult or children Adult (18þ) 553 (98%)
Pediatric (2-17) 14 (2%)
Patient age at registration (yr) 51.0 2.0 79.0
Patient age at transplant (yr) 50.2 1.3 78.9
Patient gender Female 241 (43%)
Male 326 (57%)
Patient race Black 16 (3%)
American Indian/Alaskan Native 2 (<1%)
Asian 25 (4%)
Native Hawaiian/Paciﬁc Islander 2 (<1%)
White 510 (90%)
Multirace 7 (1%)
Unknown 5 (1%)
Ethnicity (n ¼ 565) Hispanic 29 (5%)
Not Hispanic 536 (95%)
Months from transplant to enrollment 11.9 2.9 294.2
Months from transplant to chronic GVHD onset 7.3 1.2 291
Months from chronic GVHD onset to enrollment 1.8 0 32.5
Diagnosis AML 190 (34%)
ALL 66 (12%)
CML 29 (5%)
CLL 46 (8%)
MDS 84 (15%)
NHL 80 (14%)
HD 17 (3%)
MM 29 (5%)
AA 7 (1%)
Other 19 (3%)
Disease status at transplant (n ¼ 563) Early 184 (33%)
Intermediate 241 (43%)
Advanced 138 (24%)
Graft source Bone marrow 38 (7%)
Cord blood 26 (4%)
Peripheral blood 503 (89%)
Conditioning type (n ¼ 564) Myeloablative 326 (58%)
Nonmyeloablative 238 (42%)
Donor-patient CMV status (n ¼ 562) Patient and donor CMV both negative 188 (33%)
Patient or donor CMV positive 374 (67%)
Donor-patient gender combination (n ¼ 562) Female into male 164 (29%)
Others 398 (71%)
Donor match (n ¼ 565) Matched related 240 (42%)
Matched unrelated 236 (42%)
Mismatched 89 (16%)
Prior acute GVHD Yes 376 (66%)
No 191 (34%)
Karnofsky performance score at onset 80% þ 348 (61%)
< 80% 95 (17%)
Missing 124 (22%)
GHVD indicates graft-versus-host disease; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia;
CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; HD, Hodgkin lymphoma; MM, multiple myeloma; AA,
aplastic anemia; CMV, cytomegalovirus.
N ¼ 567 unless otherwise speciﬁed.
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on patients’ functional ability, symptom burden, and QOL. The assessments
performed reﬂect the recommendations of the NIH Consensus Conference
and are described brieﬂy in the following sections and in the published
cohort study rationale and design summary [17].
Functional Assessments
Functional measures examined in this analysis include standardized
hand grip strength and 2-minute walk test. In the assessment of grip
strength, a series of 3 measurements are made using a portable electronicdynamometer [18,19]. In the conduct of the 2-minute walk test, the patient
is instructed to walk a 50-foot course with 180 turns at each end, and the
total distance covered is recorded [19-21].
Patient-Reported Outcomes
The Lee Chronic GVHD Symptom Scale is a 30-item, 7-subscale symptom
scale that evaluates adverse effects of chronic GVHD on skin, vitality, lung,
nutritional status, psychological functioning, eye, and mouth symptoms
[22]. The Human Activity Proﬁle (HAP) is a 94-item self-reported assessment
of energy expenditure and physical ﬁtness. The instrument was ﬁrst
Table 2
Chronic GVHD Characteristics and Assessments
Characteristics Category No. Patients Included Count (%) Median Min Max
Clinician 0-3 GI tract score None 567 390 (69%)
Mild 137 (24%)
Moderate 38 (7%)
Severe 2 (<1%)
Clinician GI esophagus score None 567 477 (84%)
Mild 67 (12%)
Moderate 13 (2%)
Severe 10 (2%)
Clinician upper GI score None 567 451 (80%)
Mild 76 (13%)
Moderate 28 (5%)
Severe 12 (2%)
Clinician lower GI score None 567 491 (87%)
Mild 52 (9%)
Moderate 19 (3%)
Severe 5 (1%)
Clinician 0-3 liver score None 563 273 (48%)
Mild 155 (28%)
Moderate 89 (16%)
Severe 46 (8%)
NIH 0-3 chronic GVHD global severity score Less than mild 567 53 (9%)
Moderate 293 (52%)
Severe 221 (39%)
Total serum bilirubin (mg/dL) 562 .6 .1 17.9
Alkaline phosphatase (units/L) 564 96.0 0 936
Alanine aminotransferase (units/L) 564 43.0 2.0 972
Walk test (feet) 480 500 170 1150
Grip strength (lb) 534 59.9 2.0 167
Lee symptom skin score 483 15.0 0 100
Lee symptom energy score 481 32.1 0 100
Lee symptom lung score 483 5.0 0 70.0
Lee symptom eye score 481 25.0 0 100
Lee symptom nutrition score 481 5.0 0 70.0
Lee symptom psychological score 478 25.0 0 100
Lee symptom mouth score 483 12.5 0 100
Lee symptom overall score 483 20.3 0 65.3
FACT physical well-being score 466 22.0 1.0 28.0
FACT social/family well-being score 466 23.2 0 28.0
FACT emotional well-being score 467 19.0 4.0 24.0
FACT functional well-being score 466 16.0 2.0 28.0
FACT-BMT total score 466 27.0 10.0 40.0
FACT-BMT trial outcome index (TOI) 464 64.0 22.0 95.0
FACT-G score 461 80.0 23.0 108
FACT-BMT total score 461 106 36.0 146
SF-36 physical component scale (PCS) 454 39.2 15.3 60.7
SF-36 mental component scale (MCS) 454 49.8 15.3 68.4
HAP maximum activity score 466 73.0 36.0 94.0
HAP adjusted activity score 466 62.0 14.0 94.0
GHVD indicates grant-versus-host disease; PCS, physical component score; MCS, mental component score; HAP, human activity proﬁle.
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validated in an HCT population [23,24]. Respondents indicate whether they
never performed, have stopped performing, or are still performing the listed
activities. A maximum activity score (MAS) and adjusted activity score (AAS)
are calculated. The FACT-BMT v4.0 is a 37-item self-report questionnaire,
which includes a 10-item bone marrow transplantation subscale. The
instrument measures the effect of cancer therapy on multiple QOL domains,
including physical, functional, social/family, and emotional well-being and
BMT-speciﬁc concerns. Individual domain scores can be summarized to
give a total FACT-BMT score (including all subscales) or a FACT-TOI (phys-
ical þ functional þ bone marrow transplantation subscale) [25,26]. The
SF-36 v2 is a 36-item self-report questionnaire that assesses health and
functioning. The instrument examines the following domains: physical
functioning, role functioning-physical, bodily pain, general health, vitality,
social functioning, role functioning-emotional, and mental health. Two
summary scales from the SF-36 include the physical component score (PCS)
and the mental component score (MCS) [27-31].
Statistical Methods
Patient, transplantation, and chronic GVHD characteristics of the study
subjects were summarized with descriptive statistics including median and
range or frequencies according to the nature of the data. The site of GI
involvement was characterized by the treating clinician as none, esophageal,
upper GI, or lower GI, either alone or in combination. Biopsy conﬁrmationwasnot required for diagnosis. Hepatic involvement was characterized as either
none or elevation of bilirubin, alkaline phosphatase (AP), or alanine amino-
transferase (ALT) over the upper limit of normal, which was calculated based
on study site-speciﬁc laboratory reference ranges. The co-occurrence of GI or
hepatic involvement was summarized and graphically represented.
At study enrollment, the association between site of GI involvement
and Lee symptom scale items was examined using logistic regression,
with P < .05 considered statistically signiﬁcant. The type of GI and hepatic
abnormalities were dichotomized as involved versus not involved: GI
involvement was deﬁned as a score greater than 0, and liver involvement
was deﬁned as a score greater than the upper limit of normal. Multivariate
models were constructed to examine the relationship of these variables
with Lee symptom overall score, QOL measures (SF-36 PCS, SF-36 MCS,
FACT-G, FACT-TOI, FACT-BMT), HAP (MAS, AAS), and functional measures
(walk test, grip strength), all with P < .05 as signiﬁcance level. Linear mixed
models were used to account for within-patient correlation and data
missing at random. Covariates adjusted in these analyses included patient
age at HCT (younger than 50 versus older than 50), patient gender, patient
education level, months from HCT to cohort enrollment (less than
12 months versus greater than 12 months), donor-patient gender combi-
nation, transplantation type, diagnosis, disease status, Karnofsky perfor-
mance status (KPS) (<80%,80%, missing), prior history of acute GVHD, case
type, platelet count at chronic GVHD onset (less than 100 versus greater
than 100), NIH global severity score, and study site.
Figure 1. Site of GI (A) and hepatic (B) involvement in study population at cohort enrollment. GI involvement deﬁned by score >0 on 0 to 3 NIH scale from clinician
survey. Hepatic involvement deﬁned by greater than upper limit of normal reference range according to cohort site-speciﬁc reference ranges (8 missing data).
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multivariate models were constructed separately utilizing only cohort
enrollment data, as well as all available enrollment and follow-up data as
time-dependent covariates, all with P < .05 signiﬁcance level. Additional
covariates considered included study site (Fred Hutchinson Cancer Research
Center [FHCRC] versus other sites), months from HCT to cohort enrollment
(less than 12 months versus greater than 12 months), case type (incident
versus prevalent), platelet count (less than 100K versus greater than 100K),
KPS (<80%,80%, missing), patient age at HCT younger than 50 versus older
than 50), donor match relation (matched related, matched unrelated, mis-
matched), donor-patient gender combination (female into male versus
others), transplantation type (myeloablative versus not), and prior history of
acute GVHD (present versus absent). NIH severity score was not included, as
its scoring contains GI and hepatic severity information. Similarly, overlap
subtype versus classic chronic GVHD was not included, as this analysis aims
to address mechanisms of the effect of overlap subtype on outcome.RESULTS
Study Population
From the overall cohort study, we restricted cases for the
purpose of this analysis to visit dates earlier than December
31, 2011. This analysis included 567 individual subjects. With
1548 follow-up visits, data from a total of 2115 visits were
used for this analysis. Characteristics of the study population
are summarized in Table 1, and chronic GVHD characteristics
and assessments are presented in Table 2. At chronic GVHD
onset, KPS was less than 80% in 17%, bilirubin was more than
2 mg/dL in 7%, and platelet count was less than 100 K/uL in
23%. Overall NIH chronic GVHD severity was mild or less in
9%, moderate in 52%, and severe in 39% at enrollment.
Patients with GI involvement (versus those without
involvement) were older and had a greater proportion with
KPS less than 80% at onset (all P < .01). Patients with hepatic
involvement (compared to those without liver involvement)
were less likely to have received umbilical cord blood as the
graft source and had greater a proportion with KPS more
than or equal to 80% and total bilirubin more than 2 mg/dL at
onset (all P < .01). For both comparisons of GI involvement
(versus no involvement) and hepatic involvement (versus no
involvement), there were no signiﬁcant differences in time
from HCT to onset of chronic GVHD. The sites of GI and
hepatic involvement at cohort enrollment are graphically
represented separately in Figure 1.Site of GI Involvement and Lee Symptom Scale Items
At study enrollment, a higher level of patient-reported
difﬁculty swallowing solids (OR, 3.02; 95% CI, 2.34 to 3.89;
P < .001) and liquids (OR, 3.91; 95% CI, 2.66 to 5.74; P < .001)were associated with clinician-reported esophageal
involvement, and patient-reported vomiting was associated
with clinician-reported upper GI involvement (OR, 2.98; 95%
CI, 1.94 to 4.58; P < .001). Higher level of patient-reported
weight loss demonstrated a signiﬁcant association with all
sites of clinician-reported GI involvement (esophageal: OR,
1.24; 95% CI, 1.02 to1.51; P ¼ .03; upper GI: OR, 1.55; 95% CI,
1.30 to 1.85; P < .001; lower GI: OR, 1.40; 95% CI, 1.14 to 1.72;
P ¼ .001). In addition, higher level of Lee symptom nutrition
scale was associated with the involvement of esophageal
(OR, 1.07; 95% CI, 1.05 to 1.09; P < .001), upper GI (OR, 1.07;
95% CI, 1.05 to 1.09; P < .001), and lower GI (OR, 1.03; 95% CI,
1.01 to 1.05; P ¼ .01).GI/Hepatic Involvement and Lee Overall Symptom Score
In multivariate analysis utilizing data from all visits,
clinician-reported esophageal involvement (P < .001) and
overall GI (NIH score 0 to 3) involvement (P ¼ .001) were
signiﬁcantly associated with Lee overall symptom score. Lee
overall symptom score was estimated to be 3.04 higher (95%
CI, 1.68 to 4.41) for esophageal involvement and 1.87 higher
(95% CI, .73 to 3.02) for overall GI involvement, after
adjusting for other signiﬁcant covariates. Conversely, upper
and lower GI involvement and all of the considered hepatic
involvement variables did not have signiﬁcant association
with the Lee overall symptom score.GI/Hepatic Involvement and Patient-Reported QOL
and HAP
Table 3 summarizes data on the relationship between
sites of GI and hepatic involvement and patient-reported
QOL and activity. The overall GI score (NIH severity, 0 to
3 score) had signiﬁcant association with SF-36 MCS and PCS,
as well as FACT-G, FACT-TOI, FACT-BMT, and HAP-MAS and
HAP-AAS. Individual sites of GI involvement largely did not
show signiﬁcant association with these studied QOL and
activity measures, except esophageal and FACT-G. Elevated
bilirubin was associated with signiﬁcantly worsened SF-36
MCS, FACT-G, FACT-TOI, FACT-BMT and also HAP-MAS and
AAS. Among other measures of hepatic chronic GVHD (AP,
ALT, overall liver score 0 to 3), only AP had signiﬁcant asso-
ciation with HAP-AAS. No other signiﬁcant relationships
were identiﬁed between these measures of hepatic chronic
GVHD and the studied QOL outcomes.
Table 3
Site of GI and Hepatic Involvement and Quality of Life and Human Activity Proﬁle Scores*
SF-36 PCS SF-36 MCS FACT G FACT TOI FACT BMT HAP MAS HAP AAS
Estimate P Value Estimate P Value Estimate P Value Estimate P Value Estimate P Value Estimate P Value Estimate P Value
Esophagus d d d d 1.68 .04 d d d d d d d d
Upper GI d d d d d d d d d d d d d d
Lower GI d d d d d d d d d d d d d d
GI 0 to 3 1.54 .002 2.86 <.001 3.81 <.001 4.29 <.001 5.70 <.001 2.19 .001 2.10 .004
Bili d d 3.44 .001 2.66 .04 3.24 .009 3.76 .03 3.78 .002 4.36 .003
ALP d d d d d d d d d d d d 2.29 .002
ALT d d d d d d d d d d d d d d
Liver 0 to 3 d d d d d d d d d d d d d d
HAP indicates human activity proﬁle; MAS, maximum activity score; AAS, adjusted activity score; AP, alkaline phosphatase; ALT, alanine aminotransferase.
Data represent results from multivariate analyses using all available visit data. Covariates adjusted included patient age at transplantation (<50 versus older),
patient gender, patient education level, months from HCT to cohort enrollment (<12 months versus higher), donor-patient gender combination (female into
male versus other), transplantation type (myeloablative versus not), source, Karnofsky performance status at onset (<80%, 80% þ, missing), case (incident,
prevalent), platelet count at enrollment (<100K versus higher), and site (Fred Hutchinson Cancer Research Center versus other centers).
* d indicates variables that were lacking signiﬁcance and dropped from multivariate models.
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Of the considered GI and hepatic variables, upper GI
involvement was associated with an estimated 31.7 feet
fewer (P < .001), and overall liver involvement was associ-
ated with an estimated 19.4 feet fewer (P ¼ .001) achieved in
the 2-minute walk test. Only in the case of upper GI
involvement did we observe signiﬁcant associationwith grip
strength (P ¼ .04).
GI/Hepatic Measure Change: Association with Clinician
Perception of Change
In this analysis, change in each considered GI and hepatic
variable was studied for its association with short-term
clinician perception of change in overall chronic GVHD
severity. In amultivariatemodel, change in lower GI (P¼ .03),
overall GI 0 to 3 score (P ¼ .004), and AP (P ¼ .008) were
signiﬁcantly associated with short-term clinician perception
of change in overall chronic GVHD severity.Table 4
Multivariate Analysis Results for Overall Survival and Nonrelapse Mortality Since E
Parameter Category Overa
P Valu
Lower GI Involved .05
Not involved
Bilirubin Involved .001
Not involved
Site FHCRC .21
Other sites
Case type Incident .37
Prevalent
Time from HCT to enrollment <12 mo .34
12 mo
Platelet <100K .03
100K
KPS <80% .005
Missing .18
80%
Age at transplant, y 50 .72
<50
Donor match Matched unrelated .75
Mismatched .57
Matched related
Donor/patient gender combination Female donor male patients .73
Others
Conditioning type Myeloablative .42
Nonmyeloablative
Prior acute GVHD Yes .66
No
FHCRC indicates Fred Hutchinson Cancer Research Center; HCT, hematopoietic cel
host disease.GI/Hepatic Involvement and Survival
Multivariate analysis results for OS and NRM are pre-
sented in detail in Tables 4 and 5. From these data, the
following most consistent ﬁndings emerge: bilirubin was
signiﬁcantly associated with both OS and NRM based on
enrollment data, as well as both OS and NRM in the time-
dependent model. As well, lower GI involvement was asso-
ciated with OS and NRM at cohort enrollment, and overall
GI score 0 to 3 was associated with OS and NRM in the time-
dependent model. Additional signiﬁcant covariates included
platelet count less than 100, and KPS less than 80%. Graphical
plots for OS and NRM stratiﬁed according to bilirubin and
lower GI involvement at enrollment are presented in
Figure 2.
Separate models were constructed to examine the asso-
ciation of GI and hepatic severity with OS and NRM, rather
than according to involvement versus no involvement. Levels
of the severity were deﬁned according to the proposed NIHnrollment
ll Survival Nonrelapse Mortality
e HR 95% HR CI P Value HR 95% HR CI
1.67 1.01 2.77 .05 1.84 1.01 3.37
1.00 1.00
2.46 1.48 4.09 .02 2.15 1.13 4.11
1.00 1.00
.77 .51 1.16 .34 .78 .47 1.30
1.00 1.00
.80 .49 1.31 .62 .86 .48 1.56
1.00 1.00
1.28 .77 2.11 .49 .81 .44 1.48
1.00 1.00
1.70 1.05 2.78 .001 2.56 1.45 4.52
1.00 1.00
1.87 1.21 2.89 <.001 2.77 1.59 4.83
1.46 .84 2.56 .01 2.48 1.25 4.93
1.00 1.00
1.08 .71 1.66 .78 .93 .55 1.57
1.00 1.00
1.08 .68 1.70 .34 1.32 .75 2.33
1.17 .68 2.01 .56 1.22 .63 2.36
1.00 1.00
.93 .60 1.43 .51 .83 .48 1.44
1.00 1.00
.84 .55 1.28 .14 .68 .41 1.14
1.00 1.00
.91 .60 1.39 .57 .86 .51 1.45
1.00 1.00
l transplantation; KPS, Karnofsky performance status; GVHD, grant-versus-
Table 5
Multivariate Analysis Results for Overall Survival and Nonrelapse Mortality Using All Data as Time-Dependent Covariates
Parameter Category Overall Survival Nonrelapse Mortality
P Value HR 95% HR CI P Value HR 95% HR CI
NIH GI 0 to 3 Involved .02 1.69 1.10 2.60 .02 1.89 1.13 3.15
Not involved 1.00 1.00
Bilirubin Involved <.001 3.73 2.16 6.46 <.001 4.44 2.32 8.52
Not involved 1.00 1.00
Site FHCRC .13 .72 .47 1.10 .27 .74 .44 1.26
Other sites 1.00 1.00
Case type Incident .77 .93 .56 1.53 .83 .94 .51 1.73
Prevalent 1.00 1.00
Time from HCT to enrollment <12 mo .17 1.43 .86 2.36 .90 .96 .52 1.80
12 mo 1.00 1.00
Platelet <100K <.001 2.70 1.64 4.44 <.001 3.57 1.98 6.45
100K 1.00 1.00
Karnofsky performance status <80% <.001 3.10 1.93 4.98 <.001 3.43 1.87 6.29
Missing .07 1.67 .97 2.89 .03 2.11 1.06 4.18
80% 1.00 1.00
Age at transplant, y 50 .90 1.03 .67 1.57 .68 .90 .53 1.51
<50 1.00 1.00
Donor match Matched unrelated .59 1.14 .72 1.81 .29 1.37 .77 2.45
Mismatched .27 1.36 .79 2.35 .33 1.39 .71 2.72
Matched related 1.00 1.00
Donor gender combination Female donor male patients .72 .92 .59 1.43 .43 .80 .46 1.39
Others 1.00 1.00
Conditioning type Myeloablative .34 .82 .54 1.24 .09 .64 .39 1.07
Nonmyeloablative 1.00 1.00
Prior acute GVHD Yes .47 .85 .56 1.31 .65 .89 .52 1.51
No 1.00 1.00
FHCRC indicates Fred Hutchinson Cancer Research Center; HCT, hematopoietic cell transplantation; GVHD, graft-versus-host disease.
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increasing lower GI severity at enrollment was signiﬁcantly
associatedwith OS (lower GI score 2/3 versus 0: HR, 2.65; 95%
CI,1.24 to 5.66; P¼ .01) andNRM (lower GI score 2/3 versus 0:
HR, 4.89; 95% CI, 2.11 to 11.34; P < .001), with progressively
increasing HR for greater severity levels. Increasing bilirubin
was also associated with OS (bilirubin score 2/3 versus 0: HR,
3.48; 95% CI, 1.60 to 7.57; P ¼ .002) and NRM (bilirubin score
2/3 versus 0: HR, 4.92; 95% CI, 2.04 to 11.85; P < .001). A
similar trend was observed for bilirubin elevation with OS
(bilirubin 2/3 versus 0: HR, 6.58; 95% CI, 2.76 to 15.68;
P < .001) and NRM in the time-dependent model (bilirubin
2/3 versus 0: HR, 9.13; 95% CI, 3.40 to 24.56; P < .001).
As a secondary analysis approach, multivariate models
were constructed to examine change in individual GI and
hepatic involvement variables from cohort enrollment to 6
months as predictors of OS and NRM from a 6-month post-
enrollment landmark. Weight loss (HR 1.69, .94 to 3.03;
P ¼ .08) demonstrated increased hazard for overall mortality,
but this did not reach our prespeciﬁed signiﬁcance level.
DISCUSSION
Although the presence of concurrent acute features such
as GI, liver, and erythematous skin involvement in the setting
of chronic GVHD manifestations confers adverse prognosis,
the association of the speciﬁc site of GI involvement and type
of hepatic laboratory test abnormality with survival,
symptom burden, quality of life, and function has not been
adequately studied. We report here results of an analysis
addressing this question using prospectively acquired
observational cohort data. These data provide important
information that may guide clinical practice and inform
design of clinical trials.
First, we have conﬁrmed the relationship between
clinician-reported site of GI involvement and patient-
reported symptom burden. Intuitive relationships werediscerned, wherein esophageal involvement was associated
with difﬁculty swallowing, upper GI involvement with vom-
iting, and all sites with weight loss. All sites of GI involvement
except lower GI were associated with nutrition. In the anal-
ysis utilizing all available data, esophageal and overall GI (0 to
3 score) were signiﬁcantly associated with the Lee overall
symptom scale. These data support the Lee Symptom Scale as
a useful measure among chronic GVHD patients with GI
involvement and suggest that the NIH 0 to 3 GI severity scale
is sensitive to this patient-reported outcome. The studied
hepatic involvement variables had no relationship with the
patient-reported overall symptom scale, suggesting that this
instrument is not a useful measure of hepatic chronic GVHD
activity in practice or in clinical trials. This ﬁnding mirrors
clinical experience inwhich asymptomatic patients may have
very abnormal liver function tests.
Second, we report extensive data on the relationship
between sites of GI and type of hepatic involvement and
patient-reported QOL and functional ability. The principal
ﬁndingwas that overall GI 0 to 3 score and bilirubin elevation
have a strong association with patient-reported QOL,
although no consistent association was detected between
upper GI, lower GI, and hepatic involvement measures (AP,
ALT, overall liver 0 to 3 score) and QOL. Overall, GI score 0 to 3
and bilirubin also had a signiﬁcant association with HAP-
MAS and HAP-AAS. Given their sensitivity to patient-
reported QOL and functional ability as well as their relative
simplicity, overall GI 0 to 3 score and bilirubin elevation are
recommended as useful measures for clinical practice and
interventions to improve or maintain patient-reported QOL
among chronic GVHD affected patients.
In the study of OS and NRM, the predominant ﬁnding of
this analysis was the signiﬁcant association between bili-
rubin elevation and both OS and NRM. The association of
bilirubin elevation and adverse prognosis among patients
with chronic GVHD is well established and supported by
Figure 2. Overall survival and nonrelapse mortality stratiﬁed by bilirubin and lower GI involvement at enrollment. (A) Overall survival in months from cohort
enrollment, stratiﬁed by bilirubin level. (B) Non-relapse mortality in months from cohort enrollment, stratiﬁed by bilirubin level. (C) Overall survival in months from
cohort enrollment, stratiﬁed by lower GI involvement. (D) Non-relapse mortality in months from cohort enrollment, stratiﬁed by lower GI involvement.
J. Pidala et al. / Biol Blood Marrow Transplant 19 (2013) 784e791790prior literature [10,14,32,33]. Alternatively, we could not
detect an association between AP or ALT with OS and NRM in
multivariate analyses. With regard to GI involvement, lower
GI (enrollment data model) and overall GI 0 to 3 score (time-
dependent model) conferred an increase hazard for
mortality. Thus, these data demonstrate that those with
elevated bilirubin levels or a higher GI score at any time, or
thosewith lower GI involvement at enrollment, are at greater
risk for mortality under current treatment approaches and
help explain the higher risks associatedwith overlap subtype
of chronic GVHD compared to classic chronic GVHD.
We acknowledge the following potential limitations of
this analysis: First, the observed frequencies of GI and
hepatic involvement reﬂect the characteristics of the study
population and are not a true incidence estimate among all
chronic GVHD-affected patients, as there may be biases atwork in selection of enrolled patients. Second, although the
study population is large, relative under representation of
sites of involvement may limit power to detect small but
important effects. For example, the relatively infrequent co-
occurrence of sites of GI and hepatic involvement limits
our ability to examine the potential synergistic effect of
multiple concurrent sites of involvement on outcome. Next,
we acknowledge that sites and severity of GI and hepatic
involvement may vary over time and with changes in
intensity of immune suppressive therapy; thus, we have
performed multivariate analyses using both enrollment data
alone and all data in time-dependent models. Another
concern is the lack of standardized chronic GVHD treatment.
In this observational study, treatment was not mandated but
rather reﬂects usual clinical practice. Insufﬁcient data on
treatment delivered limit our ability to comment on the
J. Pidala et al. / Biol Blood Marrow Transplant 19 (2013) 784e791 791impact of immune suppressive therapies delivered on the
studied outcomes. Greater immune suppressive therapy
delivered may in part explain the observed increased
mortality among patients with bilirubin elevation and
greater overall GI score. Finally, we acknowledge risk for
chronic GVHD misclassiﬁcation, particularly in the case of
hepatic laboratory test abnormalities due to medications.
This problem, however, is not particular to this study but
rather is true of routine clinical practice, as conﬁrmatory
hepatic biopsy is infrequently performed.
In summary, our results do not support the need to
capture upper GI involvement, AP, ALT, or NIH liver score
separately, as they are not associated with survival, overall
symptom burden, or QOL. However, there are important
differences in patient-reported outcomes according to GI and
hepatic involvement among chronic GVHD-affected patients.
Thosewith elevated bilirubin or a higher GI score at any time,
or lower GI involvement at cohort enrollment, have a greater
risk for mortality under current treatment approaches.ACKNOWLEDGMENTS
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